Jaguar Health (NASDAQ:JAGX) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from a Phase 3 clinical trial.This trial covers the use of crofelemer as a treatment for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. Crofelemer is already approved by the Food and Drug Administration (FDA) as a symptomatic relief of diarrhea in adult HIV/AIDS patients getting antiretroviral therapy.The bad news for investors i ...